FibroGen will present at the Oppenheimer Rare Disease Summit on December 11, 2025, in New York City.
Quiver AI Summary
FibroGen, Inc. announced its participation in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025, in New York City, where CEO Thane Wettig will join a panel discussing rare disease companies with significant upcoming catalysts. The management team will be available for one-on-one meetings with investors at the conference. FibroGen specializes in biopharmaceuticals, focusing on innovative therapies for cancer and anemia, with its drug Roxadustat approved in several countries for treating anemia in chronic kidney disease. The company is also pursuing a Phase 3 trial for Roxadustat in lower-risk myelodysplastic syndrome and is developing FG-3246, a novel antibody-drug conjugate for metastatic prostate cancer. For more details, investors can contact the company's CFO.
Potential Positives
- FibroGen will be presenting at the Oppenheimer Movers in Rare Disease Summit, highlighting the company's engagement in key industry discussions and visibility to potential investors.
- The participation of CEO Thane Wettig in a panel focused on rare disease companies showcases FibroGen's leadership and its commitment to addressing significant medical needs.
- FibroGen's established product, Roxadustat, is already approved in multiple markets for anemia treatment, reflecting the company's successful development of therapeutic solutions.
- The ongoing Phase 2 development of FG-3246, a first-in-class therapy targeting metastatic castration-resistant prostate cancer, indicates FibroGen's focus on innovative and potentially impactful treatments in serious medical conditions.
Potential Negatives
- The press release indicates that FibroGen is still evaluating the development plan for the Phase 3 trial of roxadustat in the U.S., suggesting uncertainty and potential delays in critical pipeline developments.
- FG-3246, a first-in-class antibody-drug conjugate, is only in Phase 2 development, which may reflect a longer timeline for potential market introduction compared to competitors.
FAQ
When and where is FibroGen presenting at the Oppenheimer summit?
FibroGen will present on December 11, 2025, at the Sofitel New York in New York, NY.
Who is representing FibroGen at the event?
Thane Wettig, Chief Executive Officer, will participate in a panel discussion at the summit.
What topics will be covered during FibroGen's presentation?
The panel discussion is titled "Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts."
How can investors schedule meetings with FibroGen's management team?
Interested investors should contact their representative at Oppenheimer to schedule one-on-one meetings during the conference.
What therapies is FibroGen currently developing?
FibroGen is developing roxadustat for anemia and FG-3246 for metastatic castration-resistant prostate cancer, among other therapies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$FGEN Insider Trading Activity
$FGEN insiders have traded $FGEN stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $FGEN stock by insiders over the last 6 months:
- JAMES A SCHOENECK purchased 23,567 shares for an estimated $119,484
- THANE WETTIG (CEO) has made 2 purchases buying 3,700 shares for an estimated $33,749 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$FGEN Hedge Fund Activity
We have seen 13 institutional investors add shares of $FGEN stock to their portfolio, and 32 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 42,000 shares (+12.5%) to their portfolio in Q3 2025, for an estimated $514,500
- PRIMECAP MANAGEMENT CO/CA/ removed 30,817 shares (-34.4%) from their portfolio in Q3 2025, for an estimated $377,508
- ACADIAN ASSET MANAGEMENT LLC removed 28,840 shares (-20.7%) from their portfolio in Q3 2025, for an estimated $353,290
- TWO SIGMA ADVISERS, LP removed 27,048 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $143,354
- TWO SIGMA INVESTMENTS, LP added 26,107 shares (+185.0%) to their portfolio in Q3 2025, for an estimated $319,810
- CITADEL ADVISORS LLC added 23,517 shares (+inf%) to their portfolio in Q3 2025, for an estimated $288,083
- RENAISSANCE TECHNOLOGIES LLC added 18,100 shares (+161.9%) to their portfolio in Q3 2025, for an estimated $221,725
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$FGEN Analyst Ratings
Wall Street analysts have issued reports on $FGEN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 08/07/2025
To track analyst ratings and price targets for $FGEN, check out Quiver Quantitative's $FGEN forecast page.
Full Release
SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being held on December 11, 2025, in New York, NY.
Thane Wettig, Chief Executive Officer of FibroGen, will participate in a panel titled Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts on Thursday, December 11 at 12:15 PM ET at the Sofitel New York.
FibroGen’s management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at Oppenheimer.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit
www.fibrogen.com
.
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
[email protected]
